Resource Library

Association of clinical outcomes in metastatic breast cancer patients with circulating tumor cell and circulating cell-free DNA
Ye, et al. Eur J Cancer. 2018 Dec 4;106:133-143. doi: 10.1016/j.ejca.2018.10.012.

Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial
Larsson, et al. Breast Cancer Research. 2018 Jun 8;20(48):1-14. doi: 10.1186/s13058-018-0976-0.

Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer
Rossi, et al. Clinical Cancer Research. 2017 Nov 17;23(3):560-568. doi: 10.1158/1078-0432.CCR-17-2092.

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
Liu, et al. BMC Cancer. 2013 Apr 23;13(202):1-8. doi: 10.1186/1471-2407-13-202.

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
Muller, et al. Breast Cancer Res. 2012 Aug 15;14(4):R118. doi: 10.1186/bcr3243.

Circulating tumor cells and [18F]Fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer
De Giorgi, et al. J Clin Oncol 2009 Jul 10;27(20):3303-11. doi: 10.1200/JCO.2008.19.4423. Epub 2009 May 18.

Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer
Budd, et al. Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-1769 November 1, 2006 12; 6403-09.

Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer
Cristofanilli, et al. Journal of Clinical Oncology doi: 10.1200/JCO.2005.08.140 JCO March 1, 2005 vol. 23 no. 7 1420-1430

Circulating tumor cells, disease progression, and survival in metastatic breast cancer
Cristofanilli, et al. The New England Journal of Medicine 2004 Aug 19; 351:781-791. doi: 10.1056/NEJMoa040766.

Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer
Aggarwal, et al. Ann Oncol. 2013 Feb;24(2):420-8. doi: 10.1093/annonc/mds336. Epub 2012 Oct 1.

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
Cohen, et al. J Clin Oncol. 2008 Jul 1;26(19):3213-21. doi: 10.1200/JCO.2007.15.8923.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer
Goldkorn, et al. J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.
Scher, et al. Lancet Oncol. 2009 Mar;10(3):233-9. doi: 10.1016/S1470-2045(08)70340-1. Epub 2009 Feb 11.

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
de Bono, et al. Clin Cancer Res. 2008 Oct 1;14(19):6302-9. doi: 10.1158/1078-0432.CCR-08-0872.

Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer
Danila, et al. Clin Cancer Res. 2007 Dec 1;13(23):7053-8. doi: 10.1158/1078-0432.CCR-07-1506.